ArticleBMC cardiovascular disorders2025
Association between systemic inflammation response index and advanced stages in U.S. cardiovascular-kidney-metabolic syndrome patients: a cross-sectional study using NHANES 2015-2020 data.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluative performance of triglyceride-glucose-frailty index versus surrogate insulin resistance indices for advanced cardiovascular-kidney-metabolic syndrome, cardiometabolic multimorbidity, and mortality: the role of estimated glomerular filtration rate.Cardiovascular diabetology · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe American Heart Association introduced cardiovascular-kidney-metabolic (CKM) syndrome, a highly prevalent multistage comorbidity in the U.S. We investigated the association between the systemic inflammation response index (SIRI), a new inflammatory marker, and advanced CKM syndrome.
methodsUsing National Health and Nutrition Examination Survey data (2015-2020), we classified U.S. adults into five CKM syndrome stages (0-4). CKM syndrome stages 3 or 4 were considered advanced. The SIRI is determined by the formula: (monocyte count×neutrophil count)/lymphocyte count. Multivariable weighted logistic regression was used to assess advanced CKM syndrome risk by SIRI quartiles. Mediation analysis evaluated contributions of other inflammatory factors.
resultsAmong 10,405 CKM syndrome patients, 1,730 had advanced stages. Patients in the highest SIRI quartile had an odds ratio of 1.61 (95% confidence interval: 1.25-2.08) for being in advanced stages compared to those in the lowest quartile, with a 14% risk increase per unit rise in SIRI. Receiver operating characteristic analysis indicated SIRI had superior discriminative ability over other inflammatory indices for predicting advanced CKM syndrome. Mediation analysis revealed that high sensitivity C-reactive protein accounted for a minor proportion (4.94%) of the association between SIRI and advanced CKM syndrome, suggesting SIRI captures distinct inflammatory pathways.
conclusionsElevated SIRI independently predicted advanced CKM syndrome in U.S. adults and outperformed established inflammatory biomarkers, highlighting its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.